A six-item short-form survey for measuring headache impact: The HIT-6™

By M. Kosinski, M. Bayliss, Jakob Bjorner, J. Ware, W. H. Garber, A. Batenhorst, R. Cady, C. Dahlöf, A. Dowson, S. Tepper. Quality of Life Research, 2003

1,291 citations recorded by the source corpus.

Subfields: Epidemiology, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/8537a2443cf33d92692648a8b8b8bfe8df1cc309

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. H. Diener
2. S. Aurora
3. Dw Dodick
4. C. Turkel
5. R. DeGryse
6. S. Silberstein
7. R. Lipton
8. MF Brin

Citations in the corpus

• OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial (2010, background): “OnabotulinumtoxinA-treated patients in PREEMPT 2 had improved functioning compared with placebo-treated patients, as demonstrated by a significant decline in disability (mean change from baseline in total HIT-6 score) at all time points (p .001).”
• OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial (2010, methodology): “Other a priori defined analyses included three assessments of disability and HRQoL measured by the mean change from baseline at week 24 in total Headache Impact Test (HIT)-6 score (33), the Migraine Specific Quality of Life Questionnaire [MSQ v.”